Deciding which of the available genomic tests to use - European Medical Journal

Deciding which of the available genomic tests to use

Oncology

Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in breast cancer. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, reviews the predictive and prognostic value of currently available multigene assays for the management of patients with early stage breast cancer.

This content is supported by Genomic Health, Inc.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>